Cytosorbents Corp (CTSO)

$1.03

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.98
    $1.04
    $1.03
    downward going graph

    4.61%

    Downside

    Day's Volatility :5.53%

    Upside

    0.96%

    downward going graph
  • $0.70
    $3.80
    $1.03
    downward going graph

    32.04%

    Downside

    52 Weeks Volatility :81.58%

    Upside

    72.89%

    downward going graph

Returns

PeriodCytosorbents CorpSector (Health Care)Index (Russel 2000)
3 Months
25.76%
6.5%
0.0%
6 Months
4.04%
7.1%
0.0%
1 Year
-72.89%
9.8%
0.0%
3 Years
-86.08%
14.2%
-20.2%

Highlights

Market Capitalization
56.4M
Book Value
$0.35
Earnings Per Share (EPS)
-0.58
PEG Ratio
0.0
Wall Street Target Price
3.63
Profit Margin
-75.07%
Operating Margin TTM
-50.33%
Return On Assets TTM
-32.65%
Return On Equity TTM
-115.03%
Revenue TTM
36.7M
Revenue Per Share TTM
0.78
Quarterly Revenue Growth YOY
3.5999999999999996%
Gross Profit TTM
20.7M
EBITDA
-25.7M
Diluted Eps TTM
-0.58
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.37
EPS Estimate Next Year
-0.21
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Cytosorbents Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 252.43%

Current $1.03
Target $3.63

Company Financials

FY18Y/Y Change
Revenue
20.3M
↑ 51.34%
Net Income
-17.2M
↑ 103.42%
Net Profit Margin
-84.98%
↓ 21.75%
FY19Y/Y Change
Revenue
22.8M
↑ 12.41%
Net Income
-19.3M
↑ 11.94%
Net Profit Margin
-84.63%
↑ 0.35%
FY20Y/Y Change
Revenue
39.5M
↑ 73.3%
Net Income
-7.8M
↓ 59.32%
Net Profit Margin
-19.86%
↑ 64.77%
FY21Y/Y Change
Revenue
40.1M
↑ 1.66%
Net Income
-24.6M
↑ 213.37%
Net Profit Margin
-61.23%
↓ 41.37%
FY22Y/Y Change
Revenue
29.4M
↓ 26.8%
Net Income
-32.8M
↑ 33.61%
Net Profit Margin
-111.76%
↓ 50.53%
FY23Y/Y Change
Revenue
36.3M
↑ 23.81%
Net Income
-28.5M
↓ 13.12%
Net Profit Margin
-78.43%
↑ 33.33%
Q4 FY22Q/Q Change
Revenue
7.6M
↑ 18.25%
Net Income
-766.1K
↓ 93.7%
Net Profit Margin
-10.03%
↑ 178.03%
Q1 FY23Q/Q Change
Revenue
7.9M
↑ 3.51%
Net Income
-6.8M
↑ 782.36%
Net Profit Margin
-85.46%
↓ 75.43%
Q2 FY23Q/Q Change
Revenue
8.1M
↑ 2.05%
Net Income
-6.2M
↓ 8.98%
Net Profit Margin
-76.22%
↑ 9.24%
Q3 FY23Q/Q Change
Revenue
7.8M
↓ 3.94%
Net Income
-9.2M
↑ 49.4%
Net Profit Margin
-118.56%
↓ 42.34%
Q4 FY23Q/Q Change
Revenue
8.7M
↑ 11.79%
Net Income
-5.8M
↓ 36.53%
Net Profit Margin
-67.31%
↑ 51.25%
Q1 FY24Q/Q Change
Revenue
9.8M
↑ 12.9%
Net Income
-6.4M
↑ 8.96%
Net Profit Margin
-64.97%
↑ 2.34%
FY18Y/Y Change
Total Assets
32.7M
↑ 35.86%
Total Liabilities
15.8M
↑ 14.25%
FY19Y/Y Change
Total Assets
27.4M
↓ 16.38%
Total Liabilities
24.0M
↑ 51.56%
FY20Y/Y Change
Total Assets
90.0M
↑ 228.49%
Total Liabilities
10.7M
↓ 55.21%
FY21Y/Y Change
Total Assets
89.5M
↓ 0.48%
Total Liabilities
26.9M
↑ 150.96%
FY22Y/Y Change
Total Assets
63.2M
↓ 29.36%
Total Liabilities
27.9M
↑ 3.4%
FY23Y/Y Change
Total Assets
53.3M
↓ 15.77%
Total Liabilities
30.0M
↑ 7.64%
Q4 FY22Q/Q Change
Total Assets
63.2M
↑ 1.54%
Total Liabilities
27.9M
↑ 20.44%
Q1 FY23Q/Q Change
Total Assets
57.5M
↓ 9.12%
Total Liabilities
28.5M
↑ 2.34%
Q2 FY23Q/Q Change
Total Assets
52.4M
↓ 8.73%
Total Liabilities
28.4M
↓ 0.55%
Q3 FY23Q/Q Change
Total Assets
47.6M
↓ 9.29%
Total Liabilities
29.1M
↑ 2.51%
Q4 FY23Q/Q Change
Total Assets
53.3M
↑ 11.95%
Total Liabilities
30.0M
↑ 3.17%
Q1 FY24Q/Q Change
Total Assets
47.1M
↓ 11.62%
Total Liabilities
28.1M
↓ 6.15%
FY18Y/Y Change
Operating Cash Flow
-10.8M
↑ 67.78%
Investing Cash Flow
-1.5M
↓ 9.41%
Financing Cash Flow
17.5M
↓ 13.2%
FY19Y/Y Change
Operating Cash Flow
-16.8M
↑ 54.61%
Investing Cash Flow
-1.5M
↓ 0.01%
Financing Cash Flow
8.2M
↓ 53.18%
FY20Y/Y Change
Operating Cash Flow
-5.6M
↓ 66.51%
Investing Cash Flow
-1.7M
↑ 10.27%
Financing Cash Flow
66.3M
↑ 711.33%
FY21Y/Y Change
Operating Cash Flow
-14.0M
↑ 149.51%
Investing Cash Flow
-4.3M
↑ 155.41%
Financing Cash Flow
715.2K
↓ 98.92%
FY22Y/Y Change
Operating Cash Flow
-28.2M
↑ 101.59%
Investing Cash Flow
-6.5M
↑ 50.79%
Financing Cash Flow
5.0M
↑ 593.46%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.3M
↓ 20.71%
Investing Cash Flow
-206.1K
↓ 71.24%
Financing Cash Flow
5.0M
↓ 12488.81%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.1M
↓ 41.8%
Investing Cash Flow
-682.9K
↑ 231.37%
Financing Cash Flow
684.3K
↓ 86.31%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.9M
↑ 123.06%
Investing Cash Flow
140.3K
↓ 120.54%
Financing Cash Flow
931.1K
↑ 36.07%

Technicals Summary

Sell

Neutral

Buy

Cytosorbents Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cytosorbents Corp
Cytosorbents Corp
32.05%
4.04%
-72.89%
-86.08%
-85.33%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cytosorbents Corp
Cytosorbents Corp
NA
NA
0.0
-0.37
-1.15
-0.33
NA
0.35
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cytosorbents Corp
Cytosorbents Corp
Buy
$56.4M
-85.33%
NA
-75.07%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Cytosorbents Corp

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 7.75M → 9.78M (in $), with an average increase of 11.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -5.83M → -6.35M (in $), with an average decrease of 9.0% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 114.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 155.0%

Institutional Holdings

  • Avenir Corporation

    5.84%

  • Granahan Investment Management Inc..

    5.61%

  • Skylands Capital, LLC

    5.30%

  • Vanguard Group Inc

    3.59%

  • Neuberger Berman Group LLC

    3.52%

  • Sargent Investment Group, LLC

    2.52%

Company Information

cytosorbents (nasdaq: ctso) cytosorbents corporation is a leader in critical care immunotherapy, specializing in blood purification. its flagship product, cytosorb® is approved in the european union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm"​ or "cytokine release syndrome"​ that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. these are conditions where the risk of death is extremely high, yet no effective treatments exist. cytosorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. cytosorbents'​ purification technologies are based on biocompatible, highly porous polymer beads

Organization
Cytosorbents Corp
Employees
186
CEO
Dr. Phillip P. Chan M.D., Ph.D.
Industry
Health Technology

Discover More

FAQs